Prognostic relevance of CD163 and CD8 combined with EZH2 and gain of chromosome 18 in follicular lymphoma: a study by the Lunenburg Lymphoma Biomarker Consortium

In follicular lymphoma, studies addressing the prognostic value of microenvironment-related immunohistochemical markers and tumor cell-related genetic markers have yielded conflicting results, precluding implementation in practice. Therefore, the Lunenburg Lymphoma Biomarker Consortium performed a validation study evaluating published markers. To maximize sensitivity, an end of spectrum design was applied for 122 uniformly immunochemotherapy-treated follicular lymphoma patients retrieved from international trials and registries. The criteria were: early failure, progression or lymphoma-related death <2 years versus long remission, response duration of >5 years. Immunohistochemical staining for T cells and macrophages was performed on tissue microarrays from initial biopsies and scored with a validated computer-assisted protocol. Shallow whole-genome and deep targeted sequencing was performed on the same samples. The 96/122 cases with complete molecular and immunohistochemical data were included in the analysis. EZH2 wild-type (P=0.006), gain of chromosome 18 (P=0.002), low percentages of CD8+ cells (P=0.011) and CD163+ areas (P=0.038) were associated with early failure. No significant differences in other markers were observed, thereby refuting previous claims of their prognostic significance. Using an optimized study design, this Lunenburg Lymphoma Biomarker Consortium study substantiates wild-type EZH2 status, gain of chromosome 18, low percentages of CD8+ cells and CD163+ area as predictors of early failure to immunochemotherapy in follicular lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP [-like]), while refuting the prognostic impact of various other markers.

[1]  P. Kao,et al.  Update on Diagnosis and Management , 2015 .

[2]  Marieke E. Timmerman,et al.  Smoothing waves in array CGH tumor profiles , 2009, Bioinform..

[3]  A. López-Guillermo,et al.  High numbers of tumor-infiltrating programmed cell death 1-positive regulatory lymphocytes are associated with improved overall survival in follicular lymphoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  Y. Inayama,et al.  Prognostic significance of programmed cell death‐1‐positive cells in follicular lymphoma patients may alter in the rituximab era , 2013, European journal of haematology.

[5]  Wessel N. van Wieringen,et al.  CGHcall: Calling aberrations for array CGH tumor profiles. , 2008 .

[6]  Giovanni Martinelli,et al.  Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  B. Sander,et al.  T Cells in Tumors and Blood Predict Outcome in Follicular Lymphoma Treated with Rituximab , 2011, Clinical Cancer Research.

[8]  A. Freedman,et al.  Follicular lymphoma: 2011 update on diagnosis and management , 2011, American journal of hematology.

[9]  Carsten Schrader,et al.  Tumor sclerosis but not cell proliferation or malignancy grade is a prognostic marker in advanced-stage follicular lymphoma: the German Low Grade Lymphoma Study Group. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  K. Basso,et al.  Disruption of KMT2D perturbs germinal center B cell development and promotes lymphomagenesis , 2015, Nature Medicine.

[11]  Marcel Martin.  Cutadapt removes adapter sequences from high-throughput sequencing reads , 2011 .

[12]  N. Schmitz,et al.  Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of t , 2005, Blood.

[13]  Steven J. M. Jones,et al.  Frequent mutation of histone modifying genes in non-Hodgkin lymphoma , 2011, Nature.

[14]  Bauke Ylstra,et al.  Sequencing Structural Variants in Cancer for Precision Therapeutics. , 2016, Trends in genetics : TIG.

[15]  R. Houot,et al.  Long-term follow up of the FL2000 study comparing CHVP-interferon to CHVP-interferon plus rituximab in follicular lymphoma , 2013, Haematologica.

[16]  Ash A. Alizadeh,et al.  Hierarchy in somatic mutations arising during genomic evolution and progression of follicular lymphoma. , 2012, Blood.

[17]  R. Marcus,et al.  CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. , 2005, Blood.

[18]  Birgitta Sander,et al.  A Unifying Microenvironment Model in Follicular Lymphoma: Outcome Is Predicted by Programmed Death-1–Positive, Regulatory, Cytotoxic, and Helper T Cells and Macrophages , 2010, Clinical Cancer Research.

[19]  P. Raynaud,et al.  High ratio of interfollicular CD8/FOXP3-positive regulatory T cells is associated with a high FLIPI index and poor overall survival in follicular lymphoma. , 2010, Experimental and therapeutic medicine.

[20]  Emili Montserrat,et al.  High numbers of tumor-infiltrating FOXP3-positive regulatory T cells are associated with improved overall survival in follicular lymphoma. , 2006, Blood.

[21]  R. Gascoyne,et al.  Acquired TNFRSF14 mutations in follicular lymphoma are associated with worse prognosis. , 2010, Cancer research.

[22]  Christopher A. Miller,et al.  VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. , 2012, Genome research.

[23]  Ash A. Alizadeh,et al.  Mutations in early follicular lymphoma progenitors are associated with suppressed antigen presentation , 2015, Proceedings of the National Academy of Sciences.

[24]  Dale J. Prediger,et al.  Coefficient Kappa: Some Uses, Misuses, and Alternatives , 1981 .

[25]  Andrew Lister,et al.  Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial , 2011, The Lancet.

[26]  Randy D Gascoyne,et al.  The architectural pattern of FOXP3-positive T cells in follicular lymphoma is an independent predictor of survival and histologic transformation. , 2010, Blood.

[27]  O. Elemento,et al.  The histone lysine methyltransferase KMT2D sustains a gene expression program that represses B cell lymphoma development , 2015, Nature Medicine.

[28]  Juan F. García,et al.  The presence of STAT1-positive tumor-associated macrophages and their relation to outcome in patients with follicular lymphoma. , 2006, Haematologica.

[29]  Ruud H. Brakenhoff,et al.  CGHMultiArray: exact P-values for multi-array comparative genomic hybridization data , 2005, Bioinform..

[30]  L. Staudt,et al.  Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. , 2004, The New England journal of medicine.

[31]  M. Salido,et al.  Guidelines for cytogenetic investigations in tumours , 2015, European Journal of Human Genetics.

[32]  M. A. van de Wiel,et al.  CGHregions: Dimension Reduction for Array CGH Data with Minimal Information Loss , 2007, Cancer informatics.

[33]  G. Salles,et al.  High numbers of tumor-associated macrophages have an adverse prognostic value that can be circumvented by rituximab in patients with follicular lymphoma enrolled onto the GELA-GOELAMS FL-2000 trial. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  Peter Joosten,et al.  Gene expression profiling in follicular lymphoma to assess clinical aggressiveness and to guide the choice of treatment. , 2005, Blood.

[35]  B. Sander,et al.  Entourage: the immune microenvironment following follicular lymphoma , 2012, Blood Cancer Journal.

[36]  Yanwen Jiang,et al.  Mechanisms of epigenetic deregulation in lymphoid neoplasms. , 2013, Blood.

[37]  M. Calaminici,et al.  Number of CD4+ cells and location of forkhead box protein P3-positive cells in diagnostic follicular lymphoma tissue microarrays correlates with outcome. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  B. Ylstra,et al.  High-resolution copy number profiling by array CGH using DNA isolated from formalin-fixed, paraffin-embedded tissues. , 2012, Methods in molecular biology.

[39]  Karey Shumansky,et al.  Analysis of multiple biomarkers shows that lymphoma-associated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL). , 2005, Blood.

[40]  M. Karjalainen‐Lindsberg,et al.  A High Tumor-Associated Macrophage Content Predicts Favorable Outcome in Follicular Lymphoma Patients Treated with Rituximab and Cyclophosphamide-Doxorubicin-Vincristine-Prednisone , 2007, Clinical Cancer Research.

[41]  G. Mulligan,et al.  Prespecified Candidate Biomarkers Identify Follicular Lymphoma Patients Who Achieved Longer Progression-Free Survival with Bortezomib–Rituximab Versus Rituximab , 2013, Clinical Cancer Research.

[42]  A. Rosenwald,et al.  The reliability of immunohistochemical analysis of the tumor microenvironment in follicular lymphoma: a validation study from the Lunenburg Lymphoma Biomarker Consortium , 2014, Haematologica.

[43]  Raul Rabadan,et al.  Genetics of follicular lymphoma transformation. , 2014, Cell reports.

[44]  R. Gascoyne,et al.  The Prognostic Impact of CD163-Positive Macrophages in Follicular Lymphoma: A Study from the BC Cancer Agency and the Lymphoma Study Association , 2015, Clinical Cancer Research.

[45]  Kenny Q. Ye,et al.  An integrated map of genetic variation from 1,092 human genomes , 2012, Nature.

[46]  Kelly J. Morris,et al.  Brief Report Results and Discussion , 2022 .

[47]  Robert Kridel,et al.  Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry. , 2015, The Lancet. Oncology.

[48]  L. Villela,et al.  Predictive value of Follicular Lymphoma International Prognostic Index (FLIPI) in patients with follicular lymphoma at first progression. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[49]  A. Rosenwald,et al.  Cytomorphologic, immunohistochemical, and cytogenetic profiles of follicular lymphoma: 2 types of follicular lymphoma grade 3. , 2002, Blood.

[50]  İrfan Yavaşoğlu,et al.  Follicular Lymphoma , 2015, Turkish journal of haematology : official journal of Turkish Society of Haematology.

[51]  M. Calaminici,et al.  Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma , 2013, Nature Genetics.

[52]  Richard Durbin,et al.  Sequence analysis Fast and accurate short read alignment with Burrows – Wheeler transform , 2009 .

[53]  L. Staudt,et al.  EZH2 mutations are frequent and represent an early event in follicular lymphoma. , 2013, Blood.

[54]  Daphne de Jong,et al.  Impact of the tumor microenvironment on prognosis in follicular lymphoma is dependent on specific treatment protocols , 2009, Haematologica.

[55]  C. Lynch,et al.  Improved survival of follicular lymphoma patients in the United States. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[56]  Michael Unterhalt,et al.  The composition of the microenvironment in follicular lymphoma is associated with the stage of the disease. , 2012, Human pathology.

[57]  A Rosenwald,et al.  Retracted: Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: validation of tissue microarray as a prerequisite for broad clinical applications (a study from the Lunenburg Lymphoma Biomarker Consortium) , 2007, Journal of Clinical Pathology.

[58]  Jorge S. Reis-Filho,et al.  Microarray-Based Class Discovery for Molecular Classification of Breast Cancer: Analysis of Interobserver Agreement , 2011, Journal of the National Cancer Institute.

[59]  Pieter Wesseling,et al.  DNA copy number analysis of fresh and formalin-fixed specimens by shallow whole-genome sequencing with identification and exclusion of problematic regions in the genome assembly , 2014, Genome research.

[60]  J. Cerhan,et al.  Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[61]  Philip M Kluin,et al.  Gene-expression and immunohistochemical study of specific T-cell subsets and accessory cell types in the transformation and prognosis of follicular lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[62]  P. Elson,et al.  Follicular programmed death 1-positive lymphocytes in the tumor microenvironment are an independent prognostic factor in follicular lymphoma. , 2011, Human pathology.

[63]  J. Rossi,et al.  Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study. , 2008, Blood.

[64]  E. S. Venkatraman,et al.  A faster circular binary segmentation algorithm for the analysis of array CGH data , 2007, Bioinform..

[65]  A. Rosenwald,et al.  Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy. , 2016, Blood.

[66]  P. Solal-Céligny,et al.  Follicular lymphoma international prognostic index , 2006, Blood.